English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 2 May 2013, 06:35 HKT/SGT
Share:
    

Source: INC Research, LLC
INC Research Rated "Top CRO" by Investigative Sites Globally
Company achieves top overall ranking in 2013 CenterWatch Global Investigative Site Relationship Survey, receiving the highest "excellent" scores in six out of seven working relationship categories among all CROs included in the survey

Raleigh, NC, May 2, 2013 - (ACN Newswire) - INC Research, LLC, a therapeutically focused global clinical research organization (CRO) with a Trusted Process(R) for delivering reliable results, is ranked the "Top CRO" in the 2013 CenterWatch Global Investigative Site Relationship Survey. Results of the survey were published earlier today by CenterWatch, with INC Research receiving the highest "excellent" scores in six out of seven working relationship categories among all CROs included in the survey, a reflection of the Company's continued focus on developing strategic relationships with sites.

"Quality relationships with investigative sites around the world are a critical success factor in delivering clinical trial results on time and on budget for our customers," said Jamie Macdonald, Chief Executive Officer. "This recognition is a testament to the value we provide to our partners through our people and our approach to clinical development. We are pleased that investigative sites worldwide have validated our focus on building long-lasting relationships."

INC Research was rated a top-three CRO in all 36 individual project attributes across the seven relationship categories included in the survey. The Company received some of its highest scores in maintaining a professional staff - monitors, medical experts and administrative support - and for being well organized and prepared in supporting studies. The 2013 survey also asked sites to evaluate CROs for the first time on their overall reputation in the industry, with INC being one of only four global CROs to rank in the top five in both reputation and direct working relationship quality.

CenterWatch conducted the biannual global survey of investigative sites during November/December 2012 and January 2013, soliciting online responses from principal investigators, sub-investigators and study coordinators about the quality and effectiveness of their relationships with the CROs they have worked with in the past two years. A total of 2,032 sites worldwide completed the survey - the highest response rate ever achieved for this survey - which evaluated the performance of CROs across 36 specific relationship attributes. Rankings are based on a combination of two measures: an overall relationship quality rating based on "excellent" scores from sites, and the frequency with which companies placed among the top-three rated CROs across the 36 relationship attributes measured.

INC Research's rating as the top CRO to work with is a direct reflection of the Company's dedication to providing optimal service to the investigators engaged in its studies. The Company has dedicated global departments focused specifically on enhancing site relationships and works with sites in a collaborative partnership to
improve cycle times and standardize start-up activities to drive efficiency.

About INC Research

INC Research is a therapeutically focused clinical research organization with a high-performance reputation for conducting global clinical development programs of the highest integrity. Pharmaceutical and biotechnology companies look to INC Research for a complete range of customized Phase I through Phase IV programs in all therapeutic areas and innovative pediatric and women's health trials. The company's Trusted Process(R) methodology and therapeutic foresight lead customers to more confident, better-informed drug and device development decisions. INC Research is headquartered in Raleigh, NC. For more information, please visit www.incresearch.com or follow us at @inc_research.

Contact: Lori Dorer, Media +1-513-345-1685


This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: INC RESEARCH, LLC via Thomson Reuters ONE

Topic: Awards
Source: INC Research, LLC


https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

INC Research, LLC Related News
Nov 7, 2014 08:50 HKT/SGT
INC Research Announces Pricing of Initial Public Offering
Oct 7, 2014 07:10 HKT/SGT
INC Research Files Registration Statement for Initial Public Offering
Oct 3, 2014 10:30 HKT/SGT
INC Research Demonstrates Continued Dedication to Site Relationships at 2014 SCRS Site Solutions Summit
Oct 2, 2014 07:20 HKT/SGT
INC Research Further Reinforces Commitment to Clinical Research Sites and Patients through Creation of New Leadership Role
Aug 6, 2014 03:30 HKT/SGT
INC Research's Tara Fitzgerald and Judy Swilley Named to Annual PharmaVOICE 100
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575